Please select the option that best describes you:
What are your treatment volumes for patients with gastric cancer receiving adjuvant chemoRT for a positive margin following gastrectomy and D2 nodal dissection?
Will you treat only the anastamosis and remnant stomach without elective nodal RT, or will you include elective nodal RT in your treatment fields, assuming N1-2 disease?In determining what dose to prescribe to, what dose constraints would you place on small bowel/duodenum?
Answer from: Radiation Oncologist at Academic Institution
INT-0116 remains the only positive phase III trial showing a benefit to adjuvant chemoradiation for gastric cancer. Though very few of those patients had D2 dissections, unplanned subset analyses of 0116 and comparison to a contemporaneous Korean non-randomized trial in patients with D2 dissections ...
Sign in or Register to read more